Active Biotech AB (publ) (STO:ACTI)

Sweden · Delayed Price · Currency is SEK

0.0627

-0.0002 (-0.32%)

Apr 29, 2026, 12:38 PM CET

-27.93% (1Y)

Market Cap	165.81M
Revenue (ttm)	n/a
Net Income (ttm)	-37.32M
Shares Out	2.64B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	9.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,820,991
Average Volume	54,158,263
Open	0.0629
Previous Close	0.0629
Day's Range	0.0598 - 0.0634
52-Week Range	0.0370 - 0.3400
Beta	1.34
RSI	51.41
Earnings Date	May 7, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1983

Employees 5

Stock Exchange Nasdaq Stockholm

Ticker Symbol ACTI

Full Company Profile

Financial Performance

Financial Statements

News

Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...

5 months ago - Finanz Nachrichten

Active Biotech AB Transcript: Investor Update

2 years ago - Transcripts